Literature DB >> 35124257

In vitro activity of imipenem-relebactam against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and/or meropenem-vaborbactam.

Donatella Lombardo1, Simone Ambretti1, Tiziana Lazzarotto1, Paolo Gaibani2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35124257     DOI： 10.1016/j.cmi.2022.01.025

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


× No keyword cloud information.
  4 in total

1.  In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.

Authors:  Jacqueline Findlay; Céline Rens; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2022-09-26       Impact factor: 5.938

Review 2.  New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.

Authors:  J Nicholas O'Donnell; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

3.  Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate.

Authors:  Paolo Gaibani; Gabriele Bianco; Stefano Amadesi; Matteo Boattini; Simone Ambretti; Cristina Costa
Journal:  Antimicrob Agents Chemother       Date:  2022-04-13       Impact factor: 5.938

4.  Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient.

Authors:  Paolo Gaibani; Linda Bussini; Stefano Amadesi; Michele Bartoletti; Federica Bovo; Tiziana Lazzarotto; Pierluigi Viale; Simone Ambretti
Journal:  Microorganisms       Date:  2022-04-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.